drugset / Trial / NCT02527213

Double-blind Trial of Sodium Thiosulfate for the Treatment of Pain Associated With Calcific Uremic Arteriolopathy

NCT02527213

Phase 3 Withdrawn American Regent, Inc.
RandomizedSingle-groupDouble-blindTreatment

Summary

To evaluate the efficacy of Sodium Thiosulfate (STS) compared to placebo, in reducing analgesic requirement in subjects with calcific uremic arteriolopathy (CUA) during an initial 28-day treatment phase.

Timeline

Start
2015-01-30
Primary completion
2016-08-29
Completion
2016-08-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Sodium Thiosulfate Diagnostic / imaging agent 25 g

Indications